MARKET

EFTRW

EFTRW

Effector Therapeutics Inc
EXMKT
0.0006
NaN%
Closed 09:30 03/21 EDT
OPEN
--
PREV CLOSE
0.0006
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.187
52 WEEK LOW
0.0003
MARKET CAP
--
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EFTRW last week (0310-0314)?
Weekly Report · 6d ago
Weekly Report: what happened at EFTRW last week (0303-0307)?
Weekly Report · 03/10 12:08
Weekly Report: what happened at EFTRW last week (0224-0228)?
Weekly Report · 03/03 12:07
Weekly Report: what happened at EFTRW last week (0217-0221)?
Weekly Report · 02/24 12:07
Weekly Report: what happened at EFTRW last week (0210-0214)?
Weekly Report · 02/17 12:03
Weekly Report: what happened at EFTRW last week (0203-0207)?
Weekly Report · 02/10 11:55
Weekly Report: what happened at EFTRW last week (0127-0131)?
Weekly Report · 02/03 12:01
Weekly Report: what happened at EFTRW last week (0120-0124)?
Weekly Report · 01/27 12:06
More
About EFTRW
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Webull offers eFFECTOR Therapeutics Inc stock information, including EXMKT: EFTRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EFTRW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EFTRW stock methods without spending real money on the virtual paper trading platform.